MCLA-117 in Acute Myelogenous Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Antwerp, Belgium
- Institut Gustave Roussy
Villejuif, Île-de-France Region, France
- Fondazione Policlinico Tor Vergata
Rome, Italy
- Amsterdam Umc, Location Vumc
Amsterdam, North Holland, Netherlands
- Erasmus Mc
Rotterdam, South Holland, Netherlands
- Universitair Medisch Centrum Groningen
Groningen, Netherlands
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- the University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2016
- Primary completion
- 11 May 2021
- Completion
- 11 May 2021
- Last update posted
- 6 Apr 2025
- Registered enrollment
- 80
- Registry id
- NCT03038230
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.